Certis Oncology Solutions Announces Three Abstracts Accepted for Presentation at AACR Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance ...
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17–22, ...
BIRMINGHAM, Ala.--(BUSINESS WIRE)--CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, will be presenting three abstracts at the 2019 American Association for ...
Reflecting the Company's continuing research into expanding the capabilities of the PAS across early detection applications, the accepted abstracts include: PanGIA Analysis System, a novel machine ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) announces that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American ...
Dover, DE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (ATON) (Nasdaq: ATON) and its oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, announce that ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
China-based biotech BeiGene said company scientists and advisers will present 7 abstracts at the 106th Annual Meeting of the American Association for Cancer Research (AACR), which is being held in ...
SOUTH SAN FRANCISCO, Calif., May 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of ...
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of differentiated targeted radiotherapies, ...
STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results